search
Back to results

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Primary Purpose

Multiple Myeloma

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
P-BCMA-101 CAR-T cells
Rimiducid
Sponsored by
Poseida Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Myeloma focused on measuring CAR-T cells

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males or females, ≥18 years of age
  • Must have a confirmed diagnosis of active MM
  • Must have measurable MM
  • Must have relapsed / refractory MM, having received treatment with proteasome inhibitor and IMiD [Phase 2: Must have relapsed / refractory MM, and refractory to last line of therapy, having received treatment with proteasome inhibitor, an IMiD, CD38 targeted therapy and undergone autologous stem cell transplant (ASCT) or not a candidate for ASCT.]
  • Must have adequate hepatic, renal, cardiac and hematopoietic function

Exclusion Criteria:

  • Is pregnant or lactating
  • Has inadequate venous access and/or contraindications to leukapheresis
  • Has active hemolytic anemia, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, disseminated intravascular coagulation, leukostasis, amyloidosis, significant autoimmune, CNS or other malignant disease
  • Has an active second malignancy (not disease-free for at least 5 years) in addition to MM, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma.
  • Has active autoimmune disease
  • Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy, etc.
  • Has an active systemic infection
  • Has hepatitis B or C virus, human immunodeficiency virus (HIV), or human T-lymphotropic virus (HTLV) infection, or any immunodeficiency syndrome.
  • Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol
  • Has receiving immunosuppressive or other contraindicated therapies within the excluded time frame from entry
  • Has CNS metastases or symptomatic CNS involvement
  • Has a history of having undergone allogeneic stem cell transplantation, or any other allogeneic or xenogeneic transplant, or has undergone autologous transplantation within 90 days.
  • Unable to take acetylsalicylic acid (ASA) daily as prophylactic anticoagulation. (Cohorts R and RP only).
  • History of thromboembolic disease within the past 6 months, regardless of anticoagulation (Cohorts R and RP only).

Sites / Locations

  • Banner MD Anderson Cancer Center
  • University of California Davis
  • University of California San Diego
  • University of California San Francisco
  • Colorado Blood Cancer Institute
  • University of Chicago
  • University of Kansas Cancer Center
  • University of Maryland Greenebaum Comprehensive Cancer Center
  • Johns Hopkins University
  • Wayne State - Karmanos Cancer Institute
  • John Theurer Cancer Center
  • University of Pennsylvania
  • Sarah Cannon Research Institute at Tennessee Oncology
  • Vanderbilt University Medical Center
  • MD Anderson Cancer Center
  • Swedish Cancer Institute

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Phase 1: P-BCMA-101 CAR-T cells

Phase 1 P-BCMA-101 CAR-T cells (Cohort A)

Phase 1 P-BCMA-101 CAR-T cells (Cohort B)

Phase 1 P-BCMA-101 CAR-T cells (Cohort C)

Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort R)

Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RP)

Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RIT)

Phase 2: P-BCMA-101 CAR-T Cells

Arm Description

Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells. Rimiducid may be administered as indicated.

Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.

Single dose given across three intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.

Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.

Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.

Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before apheresis. Rimiducid may be administered as indicated.

Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.

CAR-T cells administered via intravenous infusion as a total dose

Outcomes

Primary Outcome Measures

Phase 1: Assess the Safety of P-BCMA-101
Incidence and severity of treatment-emergent adverse events
Phase 1: Maximum Tolerated Dose of P-BCMA-101
Rate of dose limiting toxicities (DLT)
Phase 2: Assess the Safety of P-BCMA-101
Incidence and severity of treatment-emergent adverse events
Phase 2: Assess the Efficacy of P-BCMA-101 (ORR)
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Response Rate (ORR)-Percentage of patients with complete response (CR), very good partial response (VGPR), or partial response (PR).
Phase 2: Assess the Efficacy of P-BCMA-101 (DOR)
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Duration of Response (DOR)-Time from complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease.

Secondary Outcome Measures

Phase 1:Assess the Safety of P-BCMA-101
Incidence and severity of treatment-emergent adverse events
Phase 1:Assess the Feasibility P-BCMA-101
Ability to generate protocol-prescribed doses of P-BCMA-101.
Phase 1: Anti-myeloma Effect of P-BCMA-101 (ORR)
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Response Rate (ORR)-Percentage of patients with complete response (CR), very good partial response (VGPR), or partial response (PR).
Phase 1: Anti-myeloma Effect of P-BCMA-101 (TTR)
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Time to Response (TTR)-Time to complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease.
Phase 1: Anti-myeloma Effect of P-BCMA-101 (DOR)
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Duration of Response (DOR)-Time from complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease.
Phase 1: Anti-myeloma Effect of P-BCMA-101 (PFS)
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Progression Free Survival (PFS)-Time from P-BCMA-101 treatment to progressive disease.
Phase 1: Anti-myeloma Effect of P-BCMA-101 (OS)
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Survival (OS)-Duration of survival from time of treatment with P-BCMA-101.
Phase 1: The Effect of Cell Dose to Guide Selection of Doses for Further Assessment in Phase 2/3 Studies
Incidence and severity of CRS events graded using Lee criteria (Lee, 2014)
Phase 2: Incidence and Severity of Cytokine Release Syndrome (CRS)
Incidence and severity of CRS events graded using Lee criteria (Lee, 2014)
Phase 2: Evaluate Efficacy Endpoints (IL-6)
Rate of IL-6 antagonist
Phase 2: Evaluate Efficacy Endpoints (C)
Corticosteroid Use
Phase 2: Evaluate Efficacy Endpoints (R)
Rimiducid Use
Phase 2: Evaluate Efficacy Endpoints (OS)
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Survival (OS)-Duration of survival from time of treatment with P-BCMA-101.
Phase 2: Evaluate Efficacy Endpoints (PFS)
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Progression Free Survival (PFS)-Time from P-BCMA-101 treatment to progressive disease.
Phase 2: Evaluate Efficacy Endpoints (TTR)
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Time to Response (TTR)-Time to complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease.
Phase 2: Evaluate Efficacy Endpoints (MRD)
Minimum residual disease negative rate

Full Information

First Posted
September 13, 2017
Last Updated
May 26, 2023
Sponsor
Poseida Therapeutics, Inc.
Collaborators
California Institute for Regenerative Medicine (CIRM)
search

1. Study Identification

Unique Protocol Identification Number
NCT03288493
Brief Title
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Official Title
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Terminated
Why Stopped
Phase I portion of the study was completed. The phase II portion of the study was terminated early to focus on an Allogeneic BCMA CAR-T program.
Study Start Date
September 20, 2017 (Actual)
Primary Completion Date
April 27, 2022 (Actual)
Study Completion Date
April 27, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Poseida Therapeutics, Inc.
Collaborators
California Institute for Regenerative Medicine (CIRM)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase 2, open-label, efficacy and safety study. Rimiducid may be administered as indicated.
Detailed Description
Phase 1 follows a 3 + 3 design of dose-escalating cohorts. Phase 2 of the study is an open-label multi-center efficacy and safety study. After a patient enrolls, leukapheresis will be performed to obtain peripheral blood mononuclear cells which will be sent to a manufacturing site to produce P-BCMA-101 CAR-T cells. The cells will then be returned to the investigational site and, after a standard chemotherapy based conditioning regimen, will be administered to the patient across 1-3 infusions, with or without combination therapy. Treated patients will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Myeloma
Keywords
CAR-T cells

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
Phase 1: open label, 3 + 3 design of dose-escalating cohorts Phase 2: open label, administered as a total dose
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
105 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Phase 1: P-BCMA-101 CAR-T cells
Arm Type
Experimental
Arm Description
Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells. Rimiducid may be administered as indicated.
Arm Title
Phase 1 P-BCMA-101 CAR-T cells (Cohort A)
Arm Type
Experimental
Arm Description
Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
Arm Title
Phase 1 P-BCMA-101 CAR-T cells (Cohort B)
Arm Type
Experimental
Arm Description
Single dose given across three intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
Arm Title
Phase 1 P-BCMA-101 CAR-T cells (Cohort C)
Arm Type
Experimental
Arm Description
Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
Arm Title
Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort R)
Arm Type
Experimental
Arm Description
Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
Arm Title
Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RP)
Arm Type
Experimental
Arm Description
Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before apheresis. Rimiducid may be administered as indicated.
Arm Title
Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RIT)
Arm Type
Experimental
Arm Description
Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
Arm Title
Phase 2: P-BCMA-101 CAR-T Cells
Arm Type
Experimental
Arm Description
CAR-T cells administered via intravenous infusion as a total dose
Intervention Type
Biological
Intervention Name(s)
P-BCMA-101 CAR-T cells
Intervention Description
P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a "safety switch" gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated.
Intervention Type
Drug
Intervention Name(s)
Rimiducid
Intervention Description
Rimiducid (safety switch activator) may be administered as indicated.
Primary Outcome Measure Information:
Title
Phase 1: Assess the Safety of P-BCMA-101
Description
Incidence and severity of treatment-emergent adverse events
Time Frame
Baseline through Day 28
Title
Phase 1: Maximum Tolerated Dose of P-BCMA-101
Description
Rate of dose limiting toxicities (DLT)
Time Frame
Baseline through Day 28
Title
Phase 2: Assess the Safety of P-BCMA-101
Description
Incidence and severity of treatment-emergent adverse events
Time Frame
Baseline through 24 months
Title
Phase 2: Assess the Efficacy of P-BCMA-101 (ORR)
Description
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Response Rate (ORR)-Percentage of patients with complete response (CR), very good partial response (VGPR), or partial response (PR).
Time Frame
Baseline through 24 months
Title
Phase 2: Assess the Efficacy of P-BCMA-101 (DOR)
Description
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Duration of Response (DOR)-Time from complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease.
Time Frame
Baseline through 24 months
Secondary Outcome Measure Information:
Title
Phase 1:Assess the Safety of P-BCMA-101
Description
Incidence and severity of treatment-emergent adverse events
Time Frame
Baseline through Month 24
Title
Phase 1:Assess the Feasibility P-BCMA-101
Description
Ability to generate protocol-prescribed doses of P-BCMA-101.
Time Frame
Baseline through Month 24
Title
Phase 1: Anti-myeloma Effect of P-BCMA-101 (ORR)
Description
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Response Rate (ORR)-Percentage of patients with complete response (CR), very good partial response (VGPR), or partial response (PR).
Time Frame
Baseline through Month 24
Title
Phase 1: Anti-myeloma Effect of P-BCMA-101 (TTR)
Description
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Time to Response (TTR)-Time to complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease.
Time Frame
Baseline through Month 24
Title
Phase 1: Anti-myeloma Effect of P-BCMA-101 (DOR)
Description
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Duration of Response (DOR)-Time from complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease.
Time Frame
Baseline through Month 24
Title
Phase 1: Anti-myeloma Effect of P-BCMA-101 (PFS)
Description
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Progression Free Survival (PFS)-Time from P-BCMA-101 treatment to progressive disease.
Time Frame
Baseline through Month 24
Title
Phase 1: Anti-myeloma Effect of P-BCMA-101 (OS)
Description
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Survival (OS)-Duration of survival from time of treatment with P-BCMA-101.
Time Frame
Baseline through Month 24
Title
Phase 1: The Effect of Cell Dose to Guide Selection of Doses for Further Assessment in Phase 2/3 Studies
Description
Incidence and severity of CRS events graded using Lee criteria (Lee, 2014)
Time Frame
Baseline through Month 24
Title
Phase 2: Incidence and Severity of Cytokine Release Syndrome (CRS)
Description
Incidence and severity of CRS events graded using Lee criteria (Lee, 2014)
Time Frame
Baseline through Month 24
Title
Phase 2: Evaluate Efficacy Endpoints (IL-6)
Description
Rate of IL-6 antagonist
Time Frame
Baseline through Month 24
Title
Phase 2: Evaluate Efficacy Endpoints (C)
Description
Corticosteroid Use
Time Frame
Baseline through Month 24
Title
Phase 2: Evaluate Efficacy Endpoints (R)
Description
Rimiducid Use
Time Frame
Baseline through Month 24
Title
Phase 2: Evaluate Efficacy Endpoints (OS)
Description
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Survival (OS)-Duration of survival from time of treatment with P-BCMA-101.
Time Frame
Baseline through Month 24
Title
Phase 2: Evaluate Efficacy Endpoints (PFS)
Description
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Progression Free Survival (PFS)-Time from P-BCMA-101 treatment to progressive disease.
Time Frame
Baseline through Month 24
Title
Phase 2: Evaluate Efficacy Endpoints (TTR)
Description
According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Time to Response (TTR)-Time to complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease.
Time Frame
Baseline through Month 24
Title
Phase 2: Evaluate Efficacy Endpoints (MRD)
Description
Minimum residual disease negative rate
Time Frame
Baseline through Month 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males or females, ≥18 years of age Must have a confirmed diagnosis of active MM Must have measurable MM Must have relapsed / refractory MM, having received treatment with proteasome inhibitor and IMiD [Phase 2: Must have relapsed / refractory MM, and refractory to last line of therapy, having received treatment with proteasome inhibitor, an IMiD, CD38 targeted therapy and undergone autologous stem cell transplant (ASCT) or not a candidate for ASCT.] Must have adequate hepatic, renal, cardiac and hematopoietic function Exclusion Criteria: Is pregnant or lactating Has inadequate venous access and/or contraindications to leukapheresis Has active hemolytic anemia, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, disseminated intravascular coagulation, leukostasis, amyloidosis, significant autoimmune, CNS or other malignant disease Has an active second malignancy (not disease-free for at least 5 years) in addition to MM, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma. Has active autoimmune disease Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy, etc. Has an active systemic infection Has hepatitis B or C virus, human immunodeficiency virus (HIV), or human T-lymphotropic virus (HTLV) infection, or any immunodeficiency syndrome. Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol Has receiving immunosuppressive or other contraindicated therapies within the excluded time frame from entry Has CNS metastases or symptomatic CNS involvement Has a history of having undergone allogeneic stem cell transplantation, or any other allogeneic or xenogeneic transplant, or has undergone autologous transplantation within 90 days. Unable to take acetylsalicylic acid (ASA) daily as prophylactic anticoagulation. (Cohorts R and RP only). History of thromboembolic disease within the past 6 months, regardless of anticoagulation (Cohorts R and RP only).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rajesh Belani, M.D.
Organizational Affiliation
Sponsor Executive Medical Director
Official's Role
Study Director
Facility Information:
Facility Name
Banner MD Anderson Cancer Center
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Facility Name
University of California Davis
City
Davis
State/Province
California
ZIP/Postal Code
95618
Country
United States
Facility Name
University of California San Diego
City
San Diego
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
Colorado Blood Cancer Institute
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
University of Kansas Cancer Center
City
Westwood
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Facility Name
University of Maryland Greenebaum Comprehensive Cancer Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21231
Country
United States
Facility Name
Wayne State - Karmanos Cancer Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
John Theurer Cancer Center
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Sarah Cannon Research Institute at Tennessee Oncology
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Swedish Cancer Institute
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
31215818
Citation
Miah KM, Hyde SC, Gill DR. Emerging gene therapies for cystic fibrosis. Expert Rev Respir Med. 2019 Aug;13(8):709-725. doi: 10.1080/17476348.2019.1634547. Epub 2019 Jun 27.
Results Reference
derived

Learn more about this trial

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

We'll reach out to this number within 24 hrs